Product Description
A Brain-Penetrant GPR88-Receptor-Agonist Tool Compound for In Vivo Mouse Studies. (Sourced from: https://pubs.acs.org/doi/10.1021/acs.jmedchem.4c00665)
Mechanisms of Action: GPR88 Agonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Boehringer Ingelheim
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for BI-9508](https://pryzm-maps.s3.us-west-2.amazonaws.com/666666current_maps.png)
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Central Nervous System
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|